Skip to main content

Molecular mechanisms and the vital roles of resistin, TLR 4, and NF-κB in treating type 2 diabetic complications

Abstract

Background

Type 2 diabetes in obese (≥ 25 and ≥ 30 kg/m2) patients is the foremost cause of cardiovascular complications like stroke, osteoarthritis, cancers (endometrial, breast, ovarian, liver, kidney, colon, and prostate), and vascular complications like diabetic neuropathy, diabetic and retinopathy, and diabetic nephropathy. It is recognized as a global burden disorder with high prevalence in middle-income nations which might lead to a double burden on health care professionals. Hence, this review emphasizes on understanding the complexity and vital signaling tracts involved in diabetic complications for effective treatment.

Main body

Type 2 diabetes in overweight patients induces the creation of specific ROS that further leads to changes in cellular proliferation, hypothalamus, and fringe. The resistin, TLR4, and NF-κB signalings are mainly involved in the progression of central and fringe changes such as insulin resistance and inflammation in diabetic patients. The overexpression of these signals might lead to the rapid progression of diabetic vascular complications induced by the release of proinflammatory cytokines, chemokines, interleukins, and cyclooxygenase-mediated chemicals. Until now, there has been no curative treatment for diabetes. Therefore, to effectively treat complications of type 2 diabetes, the researchers need to concentrate on the molecular mechanisms and important signaling tracts involved.

Conclusion

In this review, we suggested the molecular mechanism of STZ-HFD induced type 2 diabetes and the vital roles of resistin, TLR4, and NF-κB signalings in central, fringe changes, and development diabetic complications for its effective treatment.

Graphical abstract

Background

Diabetes is a chronic lifestyle syndrome that affects millions of the global population, and it is a significant health issue and obesity plays a vital role in developing diabetes [1]. Diabetes in obese people is a significant cause of stroke, heart attacks, renal failure, impaired vision, and amputation of the lower limb, and type 2 DM is often correlated with obesity and physical inactivity [2].

About 463 million individuals globally have suffered from diabetes and type 2 DM is significantly increasing in middle-income nations with 4.2 million deaths [3]. This is predicted to grow by 2045 to 700 million [3]. In recent years, T2DM accounted for 90–95% of diabetic cases [4].

Therefore, the treatment approaches for T2DM must be designed to reestablish or restore the β cells or its functions, in addition to improving insulin sensitivity [5]. This review indicates the importance of understanding the mechanism (pathophysiology) of disease patterns and specific signaling mechanisms for the discovery of new therapeutic candidates. For this, several animal models (spontaneous and induced) are available for the screening of various chemicals and phytopharmaceuticals. The maximum of these induced models cannot be seen as an analogy to clinical situations and the genetic models like ZDF rat and db/db mouse spontaneously develop T2DM similar to humans, but this spontaneous induction of T2DM is not observed in humans [6]. Moreover, these animal models are highly expensive and not easily available for the screening purposes of various novel chemicals. IR and hyperglycemia are attributed to type 2 diabetes in overweight people [7].

Among several type 2 diabetic animal models, the HFD-STZ-induced model is commonly using to discover the novel medicine from various sources (for instance, phytochemicals). In this study, we described the molecular mechanism of streptozotocin and high-fat diet-induced type 2 DM as this model develop similar characteristics to humans [8] and the roles of resistin, TLR4, and NF-κB signaling tracks in diabetic complications for effective treatment of diabetic vascular complications.

Main text

Molecular mechanism of HFD-STZ-induced diabetes

In brief, the streptozotocin (a glucose analog cytotoxic) migrates through the GLUT2 transporter and causes DNA alkylation at the 6th position of guanine moiety of the target β cells by transferring the CH3 group to DNA leading to DNA fragmentation [9] and protein glycosylation [10]. This results in the initiation of ADP-ribose enzyme to repair the DNA and utilization of energy as ATP which further leads to depletion of cellular ATP and NAD+ stores. This depletion consequences in the establishment of dephosphorylated proteins (substrates for xanthine oxidase) and the invention of ROS (reactive oxygen species) like oxygen and hydrogen peroxides and nitro-methyl-N-nitrosourea side-chain proteins, which can liberate hydroxyl and nitric oxide radicals [9].

Further, the excess hydroxyl radical migrates to the cytosol and activates the aconitase, leading to mitochondrial dysfunction and further ATP depletion, which causes the rigorous formation of ROS. All these ROS damage the plasma membrane and necrosis of β cells to induce programmed cell death and decreased insulin availability which causes hyperglycemia [11]. Earlier studies have reported that mitochondrial DNA abnormality, protein alkylation, and glycosylation are also evident for STZ-induced depletion of NAD+, which inhibits insulin biosynthesis and its secretion [12].

This hyperglycemia or diabetes by STZ is dependent on GLUT2 in β cells. The cytotoxicity role of STZ is still not clear. However, several in vitro and in vivo studies have stated that STZ can develop hyperglycemia due to its specific β cell necrosis and apoptosis as a result of oxidative stress and mitochondrial dysfunction [13]. It has also been reported that the cytotoxic effects of streptozotocin are dependent on time and dose to develop oxidative stress, associated alterations of GSH redox metabolism, mitochondrial respiratory, and induction of cytochrome P450 family. This result is important in understanding STZ-induced necrosis and programmed cell death (apoptosis) and the capability of pancreatic cells to breakdown other xenobiotics in stress situations [14]. The proposed molecular mechanism of STZ-HFD-induced diabetes is represented in Fig. 1.

Fig. 1
figure1

Molecular mechanism of STZ-HFD induced type 2 diabetes. : Initiation/release/damage; : Repair/remodeling; : Stimulation; : Inhibition. HFD high-fat diet, TG triglycerides, BG blood glucose, ROS reactive oxygen species, GLUT2 glucose transporter 2, ADP adenosine diphosphate, NADPH nicotinamide adenine dinucleotide phosphate, APT adenosine triphosphate, NAD nicotinamide adenine dinucleotide, XO xanthine oxidase, and free radicals (O.2, H2O2, OH., NO.)

Streptozotocin (STZ) also might cause injury to organs, particularly the kidney, liver, and those expressing GLUT2 transporter [15]. The alkylation in β cell has been described by using ethylating chemicals that are mildly toxic at O6-ethylguanine than at O6-methylation [9] and STZ also can affect insulin and glucose homeostasis [16].

HFD-induced obesity increased the levels of TGs (triglycerides) in circulation and in fat cells (adipose) that assist in the progress of IR (insulin resistance) and dysfunction of the adipose cell and tissue [17]. This further increases the insulin level in the blood (hyperinsulinemia) where the body tissues become insensitive to insulin and inflammation [18]. The pathophysiology linking to inflammation in metabolic illness and complications has stimulated interest in targeting inflammatory pathways to prevent or manage diabetic complications [19]. The mechanism of β cell damage via free radical generation is not only specific for STZ. This can be applicable for other diabetogenic chemicals (for instance, alloxan monohydrate) that induce the pancreatic β cell oxidation via free radical generation in obese individuals. Among the various methods of induction, the combination of HFD and STZ will develop similar characteristics to humans [8]. Hence, we selected this model to provide the molecular mechanism type 2 diabetes pathogenesis and to identify the various signaling pathways for effective management of diabetic complications.

Diabetic complications via NF-κB

Diabetic complications are linked with prolonged persistence of insulin resistance and hyperglycemia [20]. The elevated glucose level in the blood (hyperglycemia) induces the creation of ROS, AGEs (advanced glycation end-products) protein kinase-C (PKC), and AT-II due to increased polyol flux, hexamine flux, PKC activation, and accumulation of AGEs [21,22,23]. These intermediate biomolecules are the key factors for the activation of the NF-κB signaling pathway [21, 23]. The schematic representation of diabetic complications is shown in Fig. 2.

Fig. 2
figure2

Role of NF-κB signaling pathway in diabetic complications. : Stimulation/release; : Pathway of diabetic neuropathy; : Pathway of diabetic nephropathy; : Pathway of diabetic retinopathy; : Stimulation; : Inhibition. BGL blood glucose level, BP blood pressure, ROS reactive oxygen species, AGE/RAGE advanced glycation end products/receptor for advanced glycation endproducts, PKC protein kinase C, HbAc1 glycated hemoglobin, AT-II angiotensin II, DAG diacylglycerol, NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells, ARase aldose reductase, MAPK mitogen-activated protein kinase, ICAM intercellular adhesion molecule, NCV nerve conduction velocity, NGF nerve growth factor, iNOS inducible nitric oxide synthase, TGF-β tumor necrosis factor-beta, COX-2 cyclooxygenase-2, TNF-α tumor necrosis factor-alpha, IL-6 interleukin-6, MCP-1 monocyte chemoattractant protein-1, Bcl-2 B cell lymphoma 2, VEGF vascular endothelial growth factor, CAM cellular adhesion molecule, IL-8 interleukin-8, ET-1 endothelin 1, eNOS endothelial NOS

Diabetic neuropathy

Diabetic peripheral neuropathy (DPN) and diabetic autonomic neuropathy (DAN) are the intensive and most severe type of vascular diabetic complication and often the principal cause of a significant rise in morbidity and mortality [24] which comprises the loss of sensation; peripheral, somatic, autonomic, and motor dysfunction; axonal thickening; loss of nerve fibers; demyelination; narrowing of the neural capillary system, and elevated MAPK that leads to nerve injury [25]; the schematic representation of pathogenesis (Fig. 2). The hyperglycemic condition triggers the AGE/RAGE formation in neurons [23], and increased HbAc1 and collagen in peripheral nerves are also an additional risk factor for diabetic nephropathy [26].

The NF-κB gets activated by AGE/RAGE and causes the release of TNFα [21, 27]. The augmented concentration of sorbitol can increase due to increased polyol flux by aldose reductase (AR) and the generation of ROS in neural cells [28]. The sorbitol and ROS affect nerve conduction by inhibiting sodium-potassium ATPase which delays in conduction velocity in the nerves and weakness [29]. The overstimulation of NF-κB also leads to the infiltration of leucocytes, reduced neural growth factors (NGFs), increased TNFα, and IL-6 in nerve cells [30]. Simultaneously, the cyclooxygenase-2 (COX-2) is also gets activated as a result of the arachidonic acid pathway expression [31]. Elevated ICAM and NF-κB are noticed in sciatic-tibial nerves of diabetic rats that cause the narrowing of blood vessels and ischemia with inflammation [27]. The peroxisome proliferator-activated macromolecular receptors are declined in the nerves as a result of elevated levels of cytokines which increase neural death [32].

Diabetic nephropathy

Diabetic nephropathy is the principal reason for cardiovascular and chronic kidney diseases characterized by reduced GFR, microalbumin, and increased albumin-creatinine ratio [33]; the schematic representation of pathogenesis (Fig. 2). Renal inflammation is a significant factor in the evolution of diabetic nephropathy. Pro-inflammatory cytokine molecules are accountable for the infiltration of various macrophages, monocytes, and T cells [34, 35].

Apart from this, the leucocytes can upregulate the NF-κB in endothelial and mesangial cells [35, 36], thus stimulating MCP-1, leading to macrophage infiltration [37, 38], and increased microalbumin and renal injury [39, 40]. The activated NF-κB also activates MAPK and enhances the response of TGF-β-activated kinase (TAK1) released from the MAPK family (MAPK3K7). The TAK1 in turn stimulates the TGF-β, which develops the fibrosis and extracellular matrix accumulation [41]. MAPK also contributes to the overexpression of various genes in releasing the cytokine molecules and intracellular adhesion molecule (ICAM), JNK, and leucocyte infiltration via NF-κB activation [27]. Angiotensin-II (AT-II) also upsurges as a result of AGEs and oxidized lipids in DN patients. This triggers the NF-κB via a canonical pathway, and further inflammation can develop in the kidney and cause injury [27, 42].

Diabetic retinopathy

Diabetic retinopathy (DR) is the greatest and specific microvascular complication and leads to blindness in diabetic patients [43]. It is indicated by pericytes loss, condensing of the capillary basement membrane, cataract, capillary cellularity, microaneurysm, and blood-retinal barrier [44]. Based on its severity, the DR is classified as proliferative-diabetic-retinopathy, non-proliferative-diabetic-retinopathy, and diabetic-macular-edema [45]. As per the current information, 1/3 of the estimated 285 million diabetic patients have signs of DR [46]. The development of retinopathy in the USA was estimated at 28.5% and 4.4%, respectively [44]. The schematic representation of pathogenesis is shown in Fig. 2.

The mechanism of nephropathy in diabetic patients is not well understood and described, even though many proposed pathogenic have been described, viz. increased AGEs, increased ROS, PKC, aldose reductase, and cytokines [44, 47]. The inflammation plays a major role in DR pathogenesis, and the increased levels of ROS and AGEs activate apoptotic cell death [48].

Stimulated NF-κB will increase the specific proinflammatory mediators and cytokines like tumor necrosis factors (TNFs) and IL capsase-3 that cause inflammation and cell death [49]. Further, the inflamed cells release the nitric oxide (NO) leading to the stimulation of NO synthase, which can cause the narrowing of vessels, ischemia, and flow abnormalities [50]. The release of ICAM-1, CD18, and fibronectin enhances the infiltration of leucocytes, fibrosis of retinal space, and breakdown of the retinal-blood barrier [51].

Elevated PKC and imbalance in pro-NGF and NGF further develop the neural damage or dysfunction in the retina and enhance the polyol flux and MAPK, TNFα, and COX-2, leading to enhanced inflammation [27]. Matrix metalloproteins, especially MMP-9, also play a crucial role in angiogenesis and cell death (apoptosis) in DR. These protein levels are elevated in vitreous and retina in both animal models and diabetic patients [52]. Elevated ILs and MMP-9 also cause DNA alkylation and progression of DR [53].

HFD/obesity-induced hypothalamic, fringe changes

Obesity, a nutritional disorder, is the foremost health concern in developing countries which is the major concern in the advancement of T2D and atherosclerosis cardiovascular complications like stroke [54]. Cholesterols or triglycerides in overweight patients develop the insulin resistance and the epidemiological findings stating that insulin resistance has been related to abridged tissue sensitivity to insulin and raised pro-inflammatory mediators [55]. The schematic representation of these changes is shown in Figs. 3 and 4. These mediators are also amplified in the brain of rodents in HFD-induced metabolic inflammation, which plays a significant role in insulin resistance [56]. Primarily, this type of inflammation in the adipose tissue might lead to the release of pro-inflammatory biomolecules [57]. These mediators can able to alter sensitivity to insulin in the skeletal muscle, adipose tissue, and in the liver [57]. The HFD activates the local immune components in the mediobasal hypothalamus to release proinflammatory mediators which cause the neural injury [58].

Fig. 3
figure3

Role of resistin, TLR4, and NF-κB signalings in the development of inflammation. : Stimulation/release : Restore/repair; : Stimulation; : Inhibition. FGF21 fibroblast growth factor 21, FGFR fibroblast growth factor receptor gene, Akt protein kinase B, ERK extracellular signal-regulated kinases, MD2 myeloid differentiation factor 2, TLR4 Toll-like receptor 4, TRIRAP Toll/interleukin-1 receptor domain-containing adapter protein, NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells, Ik-B IκB kinase, mTORC1 Mammalian target of rapamycin complex 1, AMPK AMP-activated protein kinase, PI3K phosphatidylinositol-3-kinase, JAK c-Jun N-terminal kinases, MyD88 myeloid differentiation primary response 88, DR diabetic retinopathy, APPl1 adaptor protein, phosphotyrosine interacting, IR insulin resistance, α-MSH & CART α-melanocyte-stimulating hormone & cocaine and amphetamine-regulated transcript, AgRP& NPY Agouti-related protein & neuropeptide Y, GHSR growth hormone secretagogue receptor, POMC proopiomelanocortin, FA-O in SK.M skeletal muscle lipid oxidation, SoCS3 suppressor of cytokine signaling 3, PTP1B protein tyrosine phosphatase 1B, ER endoplasmic reticulum

Fig. 4
figure4

Role of resistin, TLR4, and NF-κB signalings in developing insulin resistance. : Stimulation/release; : Restore/repair; : Pathway of insulin resistance; : Physiological signalings. : Stimulation; : Inhibition. FGF21: Fibroblast growth factor 21; FGFR fibroblast growth factor receptor gene, Akt protein kinase B, ERK extracellular signal-regulated kinases, MD2 myeloid differentiation factor 2, TLR4 Toll-like receptor 4, NF-kB nuclear factor kappa-light-chain-enhancer of activated B cells, Ik-B IκB kinase, mTORC1 Mammalian target of rapamycin complex 1, AMPK AMP-activated protein kinase, PI3K phosphatidylinositol-3-kinase, JAK c-Jun N-terminal kinases, MyD88 myeloid differentiation primary response 88, DR diabetic retinopathy, APPl1 adaptor protein, phosphotyrosine interacting, IR insulin resistance, α-MSH & CART α-melanocyte-stimulating hormone & cocaine and amphetamine-regulated transcript, AgRP & NPY Agouti-related protein & neuropeptide Y, GHSR growth hormone secretagogue receptor, POMC proopiomelanocortin, FA-O in SK.M, skeletal muscle lipid oxidation, SoCS3 suppressor of cytokine signaling 3, PTP1B protein tyrosine phosphatase 1B, ER endoplasmic reticulum

The mechanism of pathogenesis of obesity-induced inflammation in the hypothalamus, and fringe insulin resistance is still not clear, but in this context, of a few potential pro-inflammatory pathways has been proposed. ROS plays a vital role in obesity and insulin resistance (IR) by inducing inflammation, oxidative stress, mitochondrial dysfunction, and ER stress [59]. JNK encourages the serine phosphorylation of IRS-1 and inhibits insulin-dependent tyrosine phosphorylation and downstream signaling [59, 60]. The NF-κB signaling activates and upregulates SOCS3, and the PTP1B proteins could be linked to inflammation and IR in the central hypothalamus [61] and the deficiency of JNK in the brain defends against HFD-induced insulin resistance [62]. The IKK-β/NF-κB pathways also have a critical part in the creation and expansion of hypothalamic insulin resistance [63]. The elevated NF-κB signaling in HFD animal models activates the mTORC1, leading to ER (endoplasmic reticulum). This triggers insulin resistance in hypotheses accelerates the obesity and type 2 diabetes progression [64]. Prolonged ER stress leads to increased buildup of stretched protein response which involves insulin resistance and inflammation in the hypothalamus [65].

Fascinatingly, the deficiency of PTP1B in mice improved insulin sensitivity in the central hypothermic region and reduced the progression of obesity and related metabolic complications [66]. TLR family protein (TLR4) also contributes to hypothalamic inflammation (HI) and IR [67]. TLR4 is the main component and target of saturated FAs in the hypothalamus and peripheral tissues that further release the pro-inflammatory mediators, thus triggering the insulin resistance and ER stress in the entire body [67].

Recent findings have reported elevated levels of Fetuin-A, a glycoprotein (TLR4 ligand) released by hepatocytes and adipose cells. Fetuin-Ais needed for FF-dependent activation of TLR and facilitates inflammation and IR. TLR4 inhibition in mice protected HFD-induced IR and inflammation [68]. The co-factor protein, myeloid differentiation factor (MyD88) is a downstream mediator for TLR4 pathways in mice, and its reduced levels defended HFD-induced obesity, blood glucose intolerance, and peripheral insulin resistance [69].

Furthermore, some reports have specified that TLR4-mediated microglia signaling pathways also have a central part in the control of ARC neural activity and feeding behavior [70]. Finally, this information strongly indicates that the TLR4 path plays a significant role in the progression of overweight, inflammation, and IR. This problem also might be varying with diet variations. The TLR4 is also involved in breast cancer progression [71]. Recent reviews have stated that resistin may potentiate the inflammation and IR by activating PLR4 and its downstream pathways, which promote central, peripheral insulin resistance, and inflammation [72].

The resistin released from the adipose tissue in rodents and macrophages in humans can encourage the release of inflammatory mediators and worsen inflammation and IR [73]. Resistin impairs peripheral insulin responsiveness [72], whereas the absence or lack of resistin or administration of antibodies against resistin improved sensitivity to insulin [74], and some reports have described incompatible results [75]. Apart from this contradiction, the resistin has a key role in the invention of pro-inflammatory agents (TNFα, LI-6, via NF-κB), which are generally involved in peripheral IR in animal models and the humans [76].

Resistin accelerates pro-inflammatory agents (TNFα, LI-6, via NF-κB), leading to deep alterations in insulin signaling mechanisms and worsening of IR [77]. Resistin also presents in the hypothalamus and regulates the inflammation in CNS [72], which has modulatory action on neurons and regulates glucose, food consumption, and lipid metabolism. This suggests that resistin has a regulatory role in obesity and IR [77], but the information about resistin-inducing hypothalamic inflammation and its receptors is not well documented.

Resistin may alter insulin receptors, AKT, and ERK1/2 protein phosphorylation in the brain [69]. This might lead to the stimulation of SOCS-3 and PTP1B (negative insulin signaling modulators) [78]. It can also activate JNK and p38 MAPK, which promotes the serine phosphorylation of IRS1. This further increase insulin resistance [60] and another proposed mechanism of resistin-causing hypothalamic inflammation and IR via impairment of adiponectin and FGF21 signaling called as insulin-sensitizing hormones [79]. Resistin treatment decreases adiponectin receptors expression centrally [69]. This protein might be mixed up in adipose-Rs signaling, which contributes to the insulin-sensitizing effect of adiponectin and also diminished FGF21 and its receptors (FGFR1 and KLB) in the hypothalamic region. This further involves the impairment of FGF21 and adiponectin signals in both humans’ and animals’ (mouse) neural cells [69].

The overexposure of resistin can decrease autophagy via suppression of many autophagy markers like LC3, ATG7, and Beclin1 [80]. This can occur by activating the TLR4 which leads to inhibition of phosphorylation of AMPK and stimulation of Akt/mTOR, which regulates autophagy. In specific, resistin decreased the level of LC3 in the arcuate nucleus through TLR4 signaling [80]. This suggests that resistin/TLR4 or both regulate the neural autophagy and might be a part of inflammation and insulin resistance in the hypothalamic region. This observation is remarkable about HFD-induced stimulation of astrocytes and microglia that are crucially involved in inflammation and IR in the hypothalamic region [81].

Conclusion

Obesity plays a vital key role in the development of central and fringe insulin resistance leading to type 2 diabetes. The resistin, TLR4, and NF-κB signaling mechanisms promote the central inflammation and insulin resistance.

The HFD-STZ diabetic model has become more popular for the assessment of new phytochemicals against type 2 diabetic complications. In this combination, the HFD develops obesity and insulin resistance (IR) and the streptozotocin can cause an insulin shortage by DNA fragmentation and induce oxidative stress in the β cells by accelerating the invention of ROS like hydroxyl, nitrogen oxide, hydrogen peroxide, and oxygen.

NF-κB is a crucial pathway in the pathogenesis of various macro- and micro-level diabetic complications. Inhibition of the NF-κB signaling cascade may provide an effective clinical correlation for diabetes to prevent complications. Although various natural, synthetic, and semi-synthetic NF-κB inhibitors are available, their clinical considerations are limited. Based on this review, it can be concluded that the resistin, TLR4, and NF-κB signaling pathways are highly focused and are the vital future targets for overcoming the central, fringe changes, and effective treatment of diabetic vascular complications.

Availability of data and materials

Not applicable

Abbreviations

ADP:

Adenosine diphosphate

AGEs:

Advanced glycation end products

AgRP & NPY:

Agouti-related protein & neuropeptide Y

Akt:

Protein kinase B

AMPK:

AMP-activated protein kinase

APPl1:

Adaptor protein, phosphotyrosine interacting

ARase:

Aldose reductase

AT-II:

Angiotensin II

ATP:

Adenosine triphosphate

ATP:

Adenosine tri-phosphate

Bcl-2:

B cell lymphoma 2

BG:

Blood glucose

BGL:

Blood glucose level

BP:

Blood pressure

CAM:

Cellular adhesion molecule

COX-2:

Cyclooxygenase-2

CYP:

Cytochrome P450

DAG:

Diacylglycerol

DN:

Diabetic nephropathy

DNA:

Deoxyribonucleic acid

eNOS:

Endothelial NOS

ER:

Endoplasmic reticulum

ERK:

Extracellular signal-regulated kinases

ET-1:

Endothelin 1

FGF21:

Fibroblast growth factor 21

FGFR:

Fibroblast growth factor receptor gene

GHSR:

Growth hormone secretagogue receptor

GLUT2:

Glucose transporter 2

GSH:

Glutathione

HbAc1:

Glycated hemoglobin

HFD:

High-fat diet

ICAM:

Intercellular adhesion molecule

Ik-B:

IκB kinase

IL-1:

Interleukin-1

IL-6:

Interleukin-6

IL-8:

Interleukin-8

iNOS:

Inducible nitric oxide synthase

IR:

Insulin resistance

IR:

Insulin resistance

JNK:

c-Jun N-terminal kinase

KLB:

β-Klotho gene

LC3:

Light chain 3

MAPK:

Mitogen-activated protein kinase

MCP-1:

Monocyte chemoattractant protein-1

MD2:

Myeloid differentiation factor 2

mTORC1:

Mammalian target of rapamycin complex 1

MYD88:

Myeloid differentiation primary response 88

NAD:

Nicotinamide adenine dinucleotide

NADPH:

Nicotinamide adenine dinucleotide phosphate

NCV:

Nerve conduction velocity

NF-kB:

Nuclear factor kappa-light-chain-enhancer of activated B cells

NF-κB:

Nuclear factor kappa-light-chain-enhancer of activated B cells

NGF:

Nerve growth factor

NO:

Nitric oxide

PI3K:

Phosphatidylinositol-3-kinase

PKC:

Protein kinase C

POMC:

Proopiomelanocortin

PTP1B:

Protein tyrosine phosphatase 1B

RAGE:

Receptor for advanced glycation endproducts

ROS:

Reactive oxygen species

SoCS3:

Suppressor of cytokine signaling 3

STZ:

Streptozotocin

TG:

Triglycerides

TLR:

Toll-like receptor 4

TNF:

Tumor necrosis factor beta

TNF-α:

Tumor necrosis factor-alpha

VEGF:

Vascular endothelial growth factor

XO:

Xanthine oxidase

ZDF:

Zucker diabetic fatty

α-MSH & CART:

α-Melanocyte-stimulating hormone & cocaine and amphetamine-regulated transcript

References

  1. 1.

    Annette B, Ramesh K, Hemachandra Reddy P (2017) Dynamics of diabetes and obesity: epidemiological perspective. Biochimica et Biophysica Acta. 1863:1026–1036

    Article  CAS  Google Scholar 

  2. 2.

    WHO (2020) Diabetes. Word health organization. https://www.who.int/news-room/fact-sheets/detail/diabetes

  3. 3.

    IDF (2020) Diabetes facts & figures. International Diabetes Federation. 9th edition. https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html

  4. 4.

    Chang WC, Wu JSB, Chen CW, Kuo PL, Chien HM, Wang YT, Shen SC (2015) Protective effect of vanillic acid against hyperinsulinemia, hyperglycemia and hyperlipidemia via alleviating hepatic insulin resistance and inflammation in high-fat diet (HFD)-fed rats. Nutrients. 7(12):9946–9959

    CAS  Article  Google Scholar 

  5. 5.

    Kristina B, Fran Stjepan N, Ivan K, Ivana PR (2018) Treatment approach to type 2 diabetes: Past, present and future. World J Diabetes. 15: 9(12):209–219

  6. 6.

    Yang-wei W, Guang-dong S, Jing S, Shu-jun L, Ji W, Xiao-hong X, Li-ning M (2013) Spontaneous type 2 diabetic rodent models. J Diabetes Res. 2013:401723

    Google Scholar 

  7. 7.

    Gaurav G, Ridhima W, Parijat P, Sachin Kumar S, Monica G, Saurabh S (2020) Obesity and diabetes: pathophysiology of obesity-induced hyperglycemia and insulin resistance. Pathophysiology of Obesity-Induced Health Complications. pp 81-97

  8. 8.

    Nasimeh V, Farzaneh R, Ahmad RS, Sharifeh K, Gholamreza D, Gilda E (2018) Novel high-fat diet formulation and streptozotocin treatment for induction of prediabetes and type 2 diabetes in rats. Adv Biomed Res. 7:107

    Article  CAS  Google Scholar 

  9. 9.

    Chinedum OE, Kate CE, Sonia C, Udeme NE (2013) Review of the mechanism of cell death resulting from streptozotocin challenge in experimental animals, its practical use and potential risk to humans. J Diabetes Metab Disord. 12:60

    Article  CAS  Google Scholar 

  10. 10.

    Abdulrahman MS, Hannah MB, Arun VED, Tiffany CYT, Lindsay MP, Jeremy GT (2018) The effect of streptozotocin-induced hyperglycemia on N-and O-linked protein glycosylation in mouse ovary. Glycobiology. 28(11):832–840

    Article  CAS  Google Scholar 

  11. 11.

    Philipp AG, Guy AR (2017) The role of oxidative stress and hypoxia in pancreatic beta-cell dysfunction in diabetes mellitus. Antioxid Redox Signal. 26(10):501–518

    Article  CAS  Google Scholar 

  12. 12.

    Gvazava IG, Rogovaya OS, Borisov MA, Vorotelyak EA, Vasiliev AV (2018) Pathogenesis of type 1 diabetes mellitus and rodent experimental models. Acta Naturae. 10(1):24–33

    CAS  Article  Google Scholar 

  13. 13.

    Wu M-Y, Giou-TY T-TL, Chia JL (2018) The oxidative stress and mitochondrial dysfunction during the pathogenesis of diabetic retinopathy. Oxid Med Cell Longev. 2018:1–13

    CAS  Google Scholar 

  14. 14.

    Arwa MT, Nahdi A, Annie J, Haider R (2017) Elucidation of molecular mechanisms of streptozotocin-induced oxidative stress, apoptosis, and mitochondrial dysfunction in Rin-5F pancreatic β-cells. Oxid Med Cell Longev. 2017:7054272

    Google Scholar 

  15. 15.

    Kahraman S, Aydin C, Elpek GO, Dirice E, Sanlioglu AD (2015) Diabetes-resistant NOR mice are more severely affected by streptozotocin compared to the diabetes-prone NOD mice: correlations with liver and kidney GLUT2 expressions. J Diabetes Res. 2015:450128

    CAS  Article  Google Scholar 

  16. 16.

    Nidal AQ, Adnan AB (2015) Impact of streptozotocin on altering normal glucose homeostasis during insulin testing in diabetic rats compared to normoglycemic rats. Drug Des DevelTher. 9:2515–2525

    Google Scholar 

  17. 17.

    Jiali L, Lina H, Leilei Z, Yerong Y (2016) Free fatty acids, not triglycerides, are associated with non-alcoholic liver injury progression in high fat diet induced obese rats. Lipids Health Dis. 15:27

    Article  CAS  Google Scholar 

  18. 18.

    Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H (2012) Ectopic fat and insulin resistance: pathophysiology and effect of diet and lifestyle interventions. Int J Endocrinol. 2012:983814

    CAS  Article  Google Scholar 

  19. 19.

    Sotirios T, Alexios SA, Evangelos O, George-Aggelos P, Georgia V, Spyridon P (2019) The role of inflammation in diabetes: current concepts and future perspectives. Eur Cardiol. 14(1):50–59

    Article  Google Scholar 

  20. 20.

    Konstantinos P, Maciej B, Eleni B, Manfredi R, Michael E (2018) Complications of diabetes 2017. Diabetes Res. 2018:3086167

    Google Scholar 

  21. 21.

    Valeska O, Soumyalekshmi N, Omar E, Claudio A, Carlos S, Felipe A (2018) Association between insulin resistance and the development of cardiovascular disease. Cardiovasc Diabetol. 17:122

    Article  CAS  Google Scholar 

  22. 22.

    Tobon VJC, Cuevas E, Torres RMA (2014) CNS Neurol. Disord Drug Targets 13(9):1615–1626

    Article  CAS  Google Scholar 

  23. 23.

    Xing L, Gao HL, Dai GY, Sun HM, Xu HQ (2016) Food advanced glycation end products aggravate the diabetic vascular complications via modulating the AGEs/RAGE pathway. Chin J Nat Med. 14(11):844–855

    Google Scholar 

  24. 24.

    Mitra T, Dilek GY, Abd AT, Dinesh S, Frank LB, Hassan F (2017) Diabetic neuropathy: current status and future prospects. journal of diabetes research. 2017:1-2

  25. 25.

    Aslam A, Singh J, Rajbhandari S (2014) Pathogenesis of painful diabetic neuropathy. Pain Res Treat. 2014:412041

    Google Scholar 

  26. 26.

    Chun-Pai Y, Cheng-Chieh L, Chia-Ing L, Chiu-Shongn L (2015) Cardiovascular risk factors increase the risks of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus. Medicine (Baltimore). 94(42):e1783

    Article  CAS  Google Scholar 

  27. 27.

    Sachin V, Suryavanshi, YA, Kulkarni (2017) NF-κβ: a potential target in the management of vascular complications of diabetes. Front Pharmacol. 8:798.

  28. 28.

    Su Bin C, Won SE, Min JS, Hyun JK, Jung HP, Yeon JC (2019) Transduced tat-aldose reductase protects hippocampal neuronal cells against oxidative stress-induced damage. Exp Neurobiol. 28(5):612–627

    Article  Google Scholar 

  29. 29.

    Chunkui Z, Limin W, Fengming N, Wei J, Jiang W, Hongliang Z (2014) Critical illness polyneuropathy and myopathy: a systematic review. Neural Regen Res. 9(1):101–110.

    Article  Google Scholar 

  30. 30.

    Lara K, Melanie JM, Anna JV, Anna LO (2019) Obesity-induced TNFα and IL-6 signaling: the missing link between obesity and inflammation—driven liver and colorectal cancers. Cancers (Basel). 11(1):24

    Google Scholar 

  31. 31.

    Shreena JD, Ben P, Avraham R (2018) Mechanisms of phytonutrient modulation of Cyclooxygenase-2 (COX-2) and inflammation related to cancer. Nutr Cancer. 70(3):350–375

    Article  CAS  Google Scholar 

  32. 32.

    Wei C, Tuo Y, Huan L, Lijuan H, Kai Z, Xiaoming H (2019) Peroxisome proliferator-activated receptor γ (PPARγ): a master gatekeeper in CNS injury and repair. Prog Neurobiol. 163(164):27–58

    Google Scholar 

  33. 33.

    Frederik P (2011) Peter R (2018) Diagnosis of diabetic kidney disease: state of the art and future perspective. Kidney Int Suppl 8(1):2–7

    Google Scholar 

  34. 34.

    Pérez-Morales RE, del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF (2019) Inflammation in diabetic kidney disease. Nephron. 143:12–16

    Article  CAS  Google Scholar 

  35. 35.

    Javier DC, Desirée Luis R, Ernesto MN, Víctor GT, Carolina HC, Carla F (2020) Inflammatory targets in diabetic nephropathy. J Clin Med. 9(2):458

    Article  CAS  Google Scholar 

  36. 36.

    Haisong Z, Shao CS (2015) NF-κB in inflammation and renal diseases. Cell Biosci. 5:63

    Article  CAS  Google Scholar 

  37. 37.

    Mariana RS, van der EM H, Lie Mulder H, Jolanda MS, Izabela A, Rodenhuis Z (2016) Mechanism and role of MCP-1 upregulation upon chikungunya virus infection in human peripheral blood mononuclear cells. Sci Rep. 6:32288

    Article  CAS  Google Scholar 

  38. 38.

    Patrick L, Pascal C, Veronique R, Edward GL, Mingyi W (2015) Chapter 2 - cellular and molecular determinants of arterial aging. Early Vascular Aging (EVA). 2015:7–16

    Google Scholar 

  39. 39.

    Ning S, Friedrich T, Linlin G (2019) NFκB and kidney injury. Front Immunol. 10:815

    Article  CAS  Google Scholar 

  40. 40.

    Nyasha C, Ophius M, Hilda M (2013) Microalbuminuria in patients with chronic kidney disease at Parirenyatwa Hospital in Zimbabwe. Pan Afr Med J. 14:39

    Google Scholar 

  41. 41.

    Meng XM, Tang PM, Li J, Lan HY (2015) TGF-β/Smad signaling in renal fibrosis. Front Physiol. 6:82

    Article  Google Scholar 

  42. 42.

    Temitope IA, LeiDu MH, Xueyan Z, QianX U, Chowdhury A, Ying S (2020) Keap1/Nrf2/ARE signaling unfolds therapeutic targets for redox imbalanced-mediated diseases and diabetic nephropathy. Biomed Pharmacother. 123:109732

    Article  CAS  Google Scholar 

  43. 43.

    Martin MN, Michael WU (2015) Diabetic retinopathy - ocular complications of diabetes mellitus. World J Diabetes. 6(3):489–499

    Article  Google Scholar 

  44. 44.

    Zhang K, Ferreyra HA, Grob S, Bedell M, Zhang JJ (2012) Diabetic retinopathy: genetics and etiologic mechanisms. In: D.R. Hinton, 5th edn. Elsevier, London

    Google Scholar 

  45. 45.

    Musat O, Cernat C, Labib M, Gheorghe A, Toma O, Zamfir M (2015) Diabetic macular edema. Rom J Ophthalmol. 59(3):133–136

    Google Scholar 

  46. 46.

    Ryan L, Tien YW, Charumathi S (2015) Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2:17

    Article  Google Scholar 

  47. 47.

    Safi SZ, Qvist R, Kumar S, Batumalaie K, Ismail IS (2014) Molecular mechanisms of diabetic retinopathy, general preventive strategies, and novel therapeutic targets. Biomed Res Int. 2014:801269

    Article  CAS  Google Scholar 

  48. 48.

    Małgorzata N, Andrzej G (2016) The role of the reactive oxygen species and oxidative stress in the pathomechanism of the age-related ocular diseases and other pathologies of the anterior and posterior eye segments in adults. Oxid Med Cell Longev. 2016:3164734

    Google Scholar 

  49. 49.

    Shinwan K, Jan TV, Borna R (2019) Cytokines in inflammatory disease. Int J Mol Sci. 20(23):6008

    Article  CAS  Google Scholar 

  50. 50.

    Noboru T, Shinichi T, Sadanobu N (2011) Nitric oxide-mediated coronary flow regulation in patients with coronary artery disease: recent advances. Int J Angiol. 20(3):121–134

    Article  Google Scholar 

  51. 51.

    Sayon R, Shruti A, Sumon R (2016) Retinal fibrosis in diabetic retinopathy. Exp Eye Res. 142:71–75

    Article  CAS  Google Scholar 

  52. 52.

    Kowluru RA, Zhong Q, Santos JM (2012) Matrix metalloproteinases in diabetic retinopathy: potential role of MMP-9. Expert. Opin Invest Drugs. 21(6):797–805

    CAS  Article  Google Scholar 

  53. 53.

    Kowluru RA, Shan Y, Mishra M (2016) Dynamic DNA methylation of matrix metalloproteinase-9 in the development of diabetic retinopathy. Lab Invest. 96(10):1040–1049

    CAS  Article  Google Scholar 

  54. 54.

    Vinay K, Abul A, Jon A (2014) Robbins & cotran pathologic basis of disease pathological basis of disease. 10th edition

  55. 55.

    Gregor MF, Hotamisligi GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol. 29:415–445

    CAS  Article  Google Scholar 

  56. 56.

    Yacir B, Mohammed T (2019) Molecular mechanisms underlying obesity-induced hypothalamic inflammation and insulin resistance: pivotal role of resistin/TLR4 pathways. Front Endocrinol (Lausanne) 10:140

    Article  Google Scholar 

  57. 57.

    Linlin C, Huidan D, Hengmin C, Jing F, Zhicai Z, Junliang D (2018) Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 9(6):7204–7218

    Article  Google Scholar 

  58. 58.

    Jais A, Brüning JC (2017) Hypothalamic inflammation in obesity and metabolic disease. J Clin Invest. 127(1):24–32

    Article  Google Scholar 

  59. 59.

    Estefania BM, Zaida AJ, Aranzazu MM, Francesca I, Irene EL, Sandra LD (2019) Relationship between oxidative stress, ER stress, and inflammation in type 2 diabetes: the battle continues. J Clin Med. 8(9):1385

    Article  CAS  Google Scholar 

  60. 60.

    Copps KD, White MF (2012) Regulation of insulin sensitivity by serine/threonine phosphorylation of insulin receptor substrate proteins IRS1 and IRS2. Diabetologia. 55(10):2565–2582

    CAS  Article  Google Scholar 

  61. 61.

    Chen Y, Hung-Yun L, Ning-Chun L, Janet DS, Shuyuan Y, Lei-Ya F (2013) Neuronal androgen receptor regulates insulin sensitivity via suppression of hypothalamic NF-κB–mediated PTP1B expression. Diabetes. 62(2):411–423

    Article  CAS  Google Scholar 

  62. 62.

    Santiago V, Julie CK, Tamera B, Dae YJ, Jason KK, Roger JD (2013) Diet-induced obesity mediated by the JNK/DIO2 signal transduction pathway. Genes Dev. 27(21):2345–2355

    Article  CAS  Google Scholar 

  63. 63.

    Douglass JD, Dorfman MD, Fasnacht R, Shaffer LD, Thaler JP (2017) Astrocyte IKKβ/NF-κB signaling is required for diet-induced obesity and hypothalamic inflammation. Mol Metab 6(4):366–373

    CAS  Article  Google Scholar 

  64. 64.

    Zhuo F, Elizabeth RG, Dongmin L (2013) Regulation of insulin synthesis and secretion and pancreatic beta-cell dysfunction in diabetes. Curr Diabetes Rev. 9(1):25–53

    Article  Google Scholar 

  65. 65.

    Fernanda G, Felice D, Sergio T (2017) Getting a “GRiP” on hypothalamic endoplasmic reticulum stress to combat obesity. Diabetes. 66(1):17–19

    Article  CAS  Google Scholar 

  66. 66.

    Aberdein N, Dambrino RJ, Carmo JM, Wang Z, Mitchell LE, Drummond HA (2018) Role of PTP1B in POMC neurons during chronic high-fat diet: sex differences in regulation of liver lipids and glucose tolerance. Am J Physiol Regul Integr Comp Physiol. 314(3):R478–R488

    Article  CAS  Google Scholar 

  67. 67.

    Rogero MM, Calder PC (2018) Obesity, inflammation, Toll-like receptor 4 and fatty acids. Nutrients. 10(4):E432

    Article  CAS  Google Scholar 

  68. 68.

    Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S (2012) Fetuin-A acts as an endogenous ligand of TLR4 to promote lipid-induced insulin resistance. Nat Med 18(8):1279–1285

    CAS  Article  Google Scholar 

  69. 69.

    Benomar Y, Amine H, Crépin D, Rifai S, Riffault L, Gertler A (2016) Central resistin/TLR4 impairs adiponectin signaling, contributing to insulin and FGF21 resistance. Diabetes. 65(4):913–926

    CAS  Article  Google Scholar 

  70. 70.

    Reis WYC, Gao Y, Tschöp MH (2015) Brain innate immunity regulates hypothalamic actuate neuronal activity and feeding behavior. Endocrinology 156(4):1303–1315

    CAS  Article  Google Scholar 

  71. 71.

    Wang CH, Wang PJ, Hsieh YC, Lo S, Lee YC, Chen YC (2018) Resistin facilitates breast cancer progression via TLR4-mediated induction of mesenchymal phenotypes and stemness properties. Oncogene. 37(5):589–600

    CAS  Article  Google Scholar 

  72. 72.

    María R, Cristina P, Eduardo M, Nilda G, Carmen M, Fernández M (2018) Central s-resistin deficiency ameliorates hypothalamic inflammation and increases whole body insulin sensitivity. Sci Rep. 8:3921

    Article  CAS  Google Scholar 

  73. 73.

    Maggie SB, Derek KH, Jessica NK, Kelsey AS, Mario K (2018) Contribution of adipose tissue inflammation to the development of type 2 diabetes mellitus. Compr Physiol. 9(1):1–58

    Google Scholar 

  74. 74.

    Md SJ, Sarah MW, Qizhi Y, Changyi C (2012) Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br J Pharmacol. 165(3):622–632

    Article  CAS  Google Scholar 

  75. 75.

    Mostafazadeh M, Haiaty S, Rastqar A, Keshvari M (2018) Correlation between resistin level and metabolic syndrome component: a review. HormMetab Res. 50(7):521–536

    CAS  Google Scholar 

  76. 76.

    Pine GM, Batugedara HM, Nair MG (2018) Here, there and everywhere: resistin-like molecules in infection, inflammation, and metabolic disorders. Cytokine. 110:442–451

    CAS  Article  Google Scholar 

  77. 77.

    Hannan AF, Culligan KG (2015) Human resistin and the RELM of inflammation in diabesity. Diabetol Metab Syndr. 7:54

    Article  CAS  Google Scholar 

  78. 78.

    Jérémie B, André KC, Ronald K (2014) Insulin receptor signaling in normal and insulin-resistant states. Cold Spring Harb Perspect Biol. 6(1):a009191

    Article  CAS  Google Scholar 

  79. 79.

    Cheng KK, Lam KS, Wang B, Xu A (2014) Signaling mechanisms underlying the insulin-sensitizing effects of adiponectin. Best Pract. Res Clin Endocrinol Metab. 28(1):3–13

    CAS  Article  Google Scholar 

  80. 80.

    Miao J, Benomar Y, Rifai S, Poizat G, Riffault L, Crépin D, Taouis M (2018) Resistin inhibits neuronal autophagy through Toll-like receptor 4. J Endocrinol. 238(1):77–89

    CAS  Article  Google Scholar 

  81. 81.

    André C, Guzman QO, Rey C, Rémus-Borel J, Clark S, Castellanos JA (2017) Inhibiting microglia expansion prevents diet-induced hypothalamic and peripheral inflammation. Diabetes. 66(4):908–919

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We are very much grateful to Miss Shalini Gudise for the technical support.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Affiliations

Authors

Contributions

VG performed all the research activities, writing, and design. BC conceived the study and participated in its design and coordination. The authors have read and approved the manuscript.

Corresponding author

Correspondence to Venkataiah Gudise.

Ethics declarations

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Gudise, V., Chowdhury, B. Molecular mechanisms and the vital roles of resistin, TLR 4, and NF-κB in treating type 2 diabetic complications. Beni-Suef Univ J Basic Appl Sci 9, 54 (2020). https://doi.org/10.1186/s43088-020-00078-4

Download citation

Keywords

  • Type 2 diabetes
  • STZ-HFD
  • Resistin, TLR4, and NF-κB signaling
\